New gene therapy in Korea on the progress.

Published: 2006-09-22 07:00:00

Updated: 2006-09-22 07:00:00

A gene therapeutic possibility showed quite a promising prospect by the local pharmaceutical industries including Dong-A, Yuhan and Kolon and the bio venture companies such as Biromed and Newgenepharm.

Biromed and Dong-A jointly developed an ischemic foot ulcer therapy, which is now on the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK